Kite Pharma Inc., of Santa Monica, Calif., said it expanded its agreement with the Netherlands Cancer Institute (NKI). Kite will receive an exclusive option to license a number of T-cell receptor gene sequences to develop and commercialize cancer immunotherapy candidates targeting solid tumors.